Parkinson's Disease
Conditions
Keywords
Autologous; iNSC; DA precursor cells; Parkinson's Disease; Cell therapy; Stereotaxic injection
Brief summary
This is a phase I, interventional, single arm, open-label, clinical study to evaluate the safety and efficacy of the striatal transplantation of autologous induced neural stem cell-derived DA precursor cells in Parkinson's Disease patients.
Detailed description
Parkinson's Disease (PD) is the second most common neurodegenerative disease, caused by progressive depletion of midbrain dopaminergic neurons in the substantia nigra pars compacta. This clinical study will include the preparation of dopaminergic neural precursor cells derived from neural stem cells through reprogramming of patient's peripheral blood mononuclear cells (PBMCs), and transplantation of the obtained cells into the brains of PD patients by stereotaxic injection. Safety, tolerability, evidence of cell survival (using PET scan), and the efficacy on PD symptoms will be assessed at different time points up to 12 months post-transplantation.
Interventions
DRUGAutologous induced neural stem cell-derived DA precursor cells
The autologous induced neural stem cell-derived DA precursor cells will be stereotactically implanted into the striatum of PD patients.
Sponsors
Xuanwu Hospital, Beijing
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Single Group Assignment
Eligibility
Sex/Gender
ALL
Age
30 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
Ages between 30 and 85 years, males or females; Diagnosed to be Parkinson's disease patients according to MDS Parkinson's disease diagnostic criteria; Disease history over 3 years; Hoehn and Yahr Stage less than or equal to 4 during the medication "on" time; Responsive to levodopa treatment (Maximum rate of improvement in MDS-UPDRS, part 3, is over 30%).
Exclusion criteria
Atypical Parkinsonian syndrome or secondary Parkinsonian syndrome; Accompanied with other central nervous system diseases; With other severe systemic diseases or dysfunction; With severe psychiatric disorders; Subjects are using hormone or cytotoxic drugs and cannot stop taking the drug during the trial; With cognitive disorders (MMSE\<24); With severe dyskinesia (MDS-UPDRS part 4, score in 4.1/4.2 ≥ 2); Subjects have undergone previous brain surgery; Subjects are long-term user of anticoagulant; Subjects have intracranial lesions which may affect the surgery or follow-up studies as assessed by imaging; Subjects are unable to undergo MRI or AV133 PET examination; Pregnancy or in preparation for pregnancy; Not suitable to participate in this clinical trial as assessed by the study investigators/physicians.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of changes during the medication "off" time in Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS), part III, in comparison with baseline values. | Within 12 months post-transplantation | Minimum score: 0; Maximum score: 132; Higher scores mean a worse outcome. |
| Incidence and severity of transplant-related adverse events. | Within 12 months post-transplantation | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of changes in Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS), part I, in comparison with baseline values. | Within 12 months post-transplantation | Minimum score: 0; Maximum score: 52; Higher scores mean a worse outcome. |
| Assessment of changes in Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS), part II, in comparison with baseline values. | Within 12 months post-transplantation | Minimum score: 0; Maximum score: 52; Higher scores mean a worse outcome. |
| Assessment of changes in Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS), part IV, in comparison with baseline values. | Within 12 months post-transplantation | Minimum score: 0; Maximum score: 24; Higher scores mean a worse outcome. |
| Assessment of changes during the medication "off" time in motor function by using Purdue Pegboard test and gait analyzer, in comparison with baseline values. | Within 12 months post-transplantation | — |
| Assessment of changes from baseline in total daily OFF time (or ratio of OFF time to daytime waking hours) at 12 months post-surgery. | Within 12 months post-transplantation | — |
| Assessment of changes in Unified Dyskinesia Rating Scale in comparison with baseline values. | Within 12 months post-transplantation | Minimum score: 0; Maximum score: 104; Higher scores mean a worse outcome. |
| Assessment of changes in daily levodopa-equivalent dose in comparison with baseline values. | Within 12 months post-transplantation | — |
| Assessment of changes in Parkinson's Disease Questionnaire (PDQ-39) in comparison with baseline values. | Within 12 months post-transplantation | — |
| Assessment of changes in AV133 PET imaging in comparison with baseline values. | Within 12 months post-transplantation | — |
| Assessment of changes in International Parkinson and Movement Disorder Society - Non-Motor Rating Scale (NMSS), in comparison with baseline values. | Within 12 months post-transplantation | Minimum score: 0; Maximum score: 960; Higher scores mean a worse outcome. |
Countries
China
Contacts
CONTACTZhiguo Chen, Ph.D.
CONTACTJinghong Ma, M.D.
Outcome results
None listed